The world is seeing a slow but steady decline in tuberculosis cases and deaths, though the victory is proving harder won than originally hoped. According to the latest Global Tuberculosis Report from the World Health Organization, about 10.6 million people developed the disease in 2025. While deaths have dropped by 35 percent over the last decade, these milestones are arriving years behind schedule, leaving tuberculosis as the deadliest single infectious agent globally.
A critical shift in how the fight is funded has emerged as international financial support begins to dwindle. To fill this gap, many governments have stepped up their own spending, with domestic investment rising 14 percent to reach 5.6 billion dollars between 2024 and 2025. WHO Director General Dr. Tedros Adhanom Ghebreyesus noted that while it is encouraging to see nations digging deeper into their own budgets to protect health gains, it remains unacceptable that over a million people still die annually from a treatable condition.
Progress remains frustratingly uneven across different parts of the globe. While Europe and Africa saw significant drops in incidence rates, other regions struggled; some saw almost no change, and in the Americas, case numbers actually rose for the fifth year in a row. These disparities highlight deep cracks in healthcare infrastructure and unequal access to basic services, particularly in thirty countries where nearly 90 percent of all global cases are now concentrated.
Beyond regional imbalances, there are worrying gaps in detection and innovation. Millions of people go undiagnosed every year, and drug resistant strains of TB remain a persistent threat with less than half of affected patients receiving necessary treatment. Perhaps most concerning is the lack of funding for future breakthroughs, as current research spending sits at less than a quarter of what is needed to develop next generation vaccines and diagnostics. The WHO warns that without a surge in political will and sustainable funding, the goal of ending the epidemic will remain out of reach.
A critical shift in how the fight is funded has emerged as international financial support begins to dwindle. To fill this gap, many governments have stepped up their own spending, with domestic investment rising 14 percent to reach 5.6 billion dollars between 2024 and 2025. WHO Director General Dr. Tedros Adhanom Ghebreyesus noted that while it is encouraging to see nations digging deeper into their own budgets to protect health gains, it remains unacceptable that over a million people still die annually from a treatable condition.
Progress remains frustratingly uneven across different parts of the globe. While Europe and Africa saw significant drops in incidence rates, other regions struggled; some saw almost no change, and in the Americas, case numbers actually rose for the fifth year in a row. These disparities highlight deep cracks in healthcare infrastructure and unequal access to basic services, particularly in thirty countries where nearly 90 percent of all global cases are now concentrated.
Beyond regional imbalances, there are worrying gaps in detection and innovation. Millions of people go undiagnosed every year, and drug resistant strains of TB remain a persistent threat with less than half of affected patients receiving necessary treatment. Perhaps most concerning is the lack of funding for future breakthroughs, as current research spending sits at less than a quarter of what is needed to develop next generation vaccines and diagnostics. The WHO warns that without a surge in political will and sustainable funding, the goal of ending the epidemic will remain out of reach.
